Johnson & Johnson stock ticks up as MACD and ADX show bullish signals: weekly analysis

Traders Union
All News
Financial News
Johnson & Johnson rises 0.78% this week

Highlights

Johnson & Johnson consolidates above medium- and long-term trend support despite recent short-term selling pressure.
Momentum signals are constructive with bullish readings on most indicators, though oscillators diverge, indicating ongoing indecision.
Shares are expected to trade between $219.50 and $232.80 next week, with a 75% probability bias to the upside.

Drug trial successes and approvals fuel bullish sentiment this week

Johnson & Johnson announced that its drug nipocalimab achieved the primary endpoint of reducing disease activity at 24 weeks in adults with moderate-to-severe systemic lupus erythematosus, according to Phase 2 JASMINE trial results. The company also gained Indian regulatory approval for the VARIPULSE Platform, a pulsed field ablation technology for atrial fibrillation. Additional PROTEUS Phase 3 data showed apalutamide in combination with hormone therapy cut the risk of metastasis or death in prostate cancer patients by 20%.

Mixed technical signals persist as consolidation phase continues over week

On the weekly chart, JNJ remains below the MA-20 but comfortably above the MA-50 and MA-200, with dynamic support near $205.38. Weekly volatility measures 3.67%, and the price action reflects modest recovery within a consolidation phase. Key oscillators show mixed signals: the MACD and ADX are bullish, while RSI signals a buy, but CCI shows a sell bias and Stochastic RSI plus Bull/Bear Power indicate oversold conditions. Primary support is at $219.50, with major resistance at $232.80.

Sideways trade favored amid breakout risk and positive momentum next week

For the next five trading days, JNJ is expected to trade mostly sideways within the $219.50 – $232.80 corridor, with about a 75% probability of an upside breakout due to generally positive momentum readings. If the price sustains a move above $232.80, further gains could target the yearly highs. If sellers regain control and JNJ breaks $219.50 to the downside, expect pressure toward medium-term supports. A period of range-bound trading and ongoing consolidation is most likely in the week ahead.

Jainam Mehta, market strategist, notes that Johnson & Johnson saw modest recovery this week, closing in the upper weekly range despite remaining below its key MA-20. He sees constructive medium- and long-term structure, with recent drug trial successes and regulatory wins reinforcing the broader bullish foundation. However, mixed signals from oscillators and the current consolidation argue for caution. "This divergence in momentum and sentiment may offer tactical range-trading opportunities between $219.50 and $232.80, but I’ll wait for a decisive move above resistance before turning more bullish for the week ahead."

Earlier, analysts noted that Johnson & Johnson was experiencing ongoing short- and medium-term selling pressure despite a supportive long-term outlook. The latest developments—buoyant clinical trial success and regulatory wins amid a consolidating price structure—suggest upside risk is building, making an upside break above $232.80 a potential catalyst for renewed momentum.

Source of Data: JNJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.